Quantum-Si Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company™, has announced the submission of a new preprint paper to BioRxiv, showcasing the power of its proprietary bioinformatics tool, ProteoVue, in detecting and quantifying Single Amino Acid Variants (SAAVs). The paper, titled “Detecting Amino Acid Variants Using Next-Generation Protein Sequencing (NGPS),” underscores the transformative potential of Quantum-Si’s Platinum® benchtop instrument in advancing the field of proteomics.
The study demonstrates how Quantum-Si’s innovative platform enables high-precision analysis of protein variants, offering new insights into protein structure and function. The preprint publication will soon be available on the BioRxiv website, providing researchers with a valuable resource for exploring next-generation approaches in protein sequencing.
Quantum-Si Incorporated (Nasdaq: QSI), The Protein Sequencing Company™, has announced the submission of a groundbreaking paper to BioRxiv, showcasing its advanced bioinformatics tool, ProteoVue. This tool, integrated within the Platinum® Analysis Software, is designed to detect and quantify a wide range of protein variations, including Single Amino Acid Variants (SAAVs), offering a transformative advancement in proteomics research.
ProteoVue is built to analyze complex protein systems with high precision. Its capabilities extend beyond traditional proteomics methods, enabling the detection of isobaric variations, the quantification of post-translational modifications, and the characterization of proteins containing unnatural amino acids. These features make it an invaluable tool for proteoform science and protein therapeutics, empowering cutting-edge research in biology and medicine.
A Breakthrough in Next-Generation Protein Sequencing
Jeff Hawkins, President and CEO of Quantum-Si, emphasized the significance of this new development, stating, “ProteoVue is a major step forward in harnessing the power of Next-Generation Protein Sequencing (NGPS™). This innovation highlights how our NGPS platform enables precise, scalable proteomic analysis, offering researchers tools to uncover protein variations crucial for understanding biology and disease.”
The preprint paper establishes ProteoVue as a comprehensive solution for detecting and quantifying SAAVs. Using Quantum-Si’s NGPS technology, ProteoVue applies advanced signal processing, neural network-driven kinetic signature modeling, and a robust clustering framework to provide unmatched insights into protein variants. This approach enables the detection of variants that are often undetectable by traditional mass spectrometry techniques.
Key Findings
- Single Molecule Variant Detection: ProteoVue demonstrates the ability to detect and quantify amino acid variants by measuring individual protein molecules in real time.
- Variant Type Differentiation: The analysis pipeline differentiates between various variant types by examining changes in the kinetic features of single molecules, providing detailed insights into protein variations.
John Vieceli, Chief Product Officer at Quantum-Si, highlighted the broader potential of ProteoVue, stating, “This paper underscores how ProteoVue can support advanced research in biomarker discovery, precision medicine, and proteomics. It’s part of our ongoing efforts to enhance the NGPS analysis pipelines for our customers.”
Quantum-Si’s collaboration with NVIDIA, announced during their Investor & Analyst Day in November 2024, will further enhance the analysis process. By leveraging AI and GPU-powered processing, Quantum-Si aims to handle the large volumes of data produced by its instruments, including the recently announced Proteus platform.
Early Access and Future Collaboration
Quantum-Si invites researchers and potential collaborators to gain early access to the ProteoVue workflow, enabling them to explore its powerful capabilities in protein variant detection. For more information, visit Protein Variant Applications.
About Quantum-Si
Quantum-Si, The Protein Sequencing Company™, is at the forefront of revolutionizing the field of proteomics. Its flagship Platinum® instrument enables Next-Gen Protein Sequencing™, driving advances in drug discovery, diagnostics, and proteomic research that surpass the capabilities of existing proteomics tools.
